Prostate-specific membrane antigen modulates the progression of prostate cancer by regulating the synthesis of arginine and proline and the expression of androgen receptors and Fos proto-oncogenes

Xi Hong *, Liang Mao *, Luwei Xu *, Qiang Hu, and Ruipeng Jia *

Department of Urology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

ABSTRACT

The expression of prostate-specific membrane antigen (PSMA) is strikingly upregulated during oncogenesis and prostate cancer (PCa) progression, but the functions of this antigen in PCa remain unclear. Here, we constructed PSMA-knockdown LNCaP and 22rv1 cell lines and performed metabolomic and transcriptomic analyses to determine the effects of PSMA on PCa metabolism and transcription. The metabolism of arginine and proline was detected using specific kits. The mRNA and protein expression levels of the identified differentially expressed genes were quantified by RT-qPCR and Western blotting. The proliferation of each cell line was evaluated through CCK-8, EdU and colony formation assays. The migration and invasion abilities of each cell line were detected using wound healing and transwell assays, respectively. PSMA knockdown led to metabolic disorder and abnormal transcription in PCas and resulted in inhibition of the proliferation and metastasis of PCa cells in vitro and in vivo. The depletion of PSMA also promoted the biosynthesis of arginine and proline, inhibited the expression of AR and PSA, and induced the expression of c-Fos and FosB. PSMA plays an important role in the metabolism, proliferation and metastasis of human PCa and may be a promising therapeutic target.

INTRODUCTION

Prostate cancer (PCa) is one of the most common malignancies of the male genitourinary system and the second leading cause of cancer-related death in men in developed countries [1]. As is well established, androgen receptor (AR) plays a critical role in PCa development and has become the most effective therapeutic target in PCa [2]. Most patients with early-stage PCa respond well to surgery, docetaxel chemotherapy and androgen deprivation therapy (ADT). Unfortunately, during treatment, the vast majority of patients will become insensitive to ADT due to the abnormal activation of the AR signaling pathway caused by the mutation and resplicing of AR [3]. Despite great advances in systemic therapies, the prognosis for patients with castration-resistant prostate cancer (CRPC) remains poor [4]. In addition, distant metastasis is an important factor leading to biochemical recurrence and poor patient prognosis [5]. Therefore, many studies have focused on the mechanism of PCa metastasis to identify potential therapeutic targets [6–8].

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein receptor with folate hydrolase activity and glutamate carboxypeptidase activity. The expression of this antigen is strongly upregulated in most cases of PCa. Due to its localization in the cell membrane, PSMA has become an effective target for in vivo imaging and drug delivery [9,10]. Although some evidence suggests that PSMA is associated with the metastasis of PCa, its function and the mechanism through which it promotes PCa progression remain unclear. Although evidence obtained from a mouse model of PCa suggests that PSMA can contribute to the progression of PCa by redirecting cell survival signaling from the MAPK to the PI3K-Akt pathway through the release of glucose as a signaling factor, its biological function in human PCa is elusive [11]. Despite its name as
a membrane antigen, PSMA is also located in the cytoplasm [12]. Due to the critical role of PSMA in targeted imaging and drug delivery, researchers may overlook its roles as a glutamate carboxypeptidase and a folate hydrolase.

In the present study, we hypothesized that PSMA, as a key enzyme, can influence cell transcription and function by modulating metabolism. We aimed to investigate the role of PSMA in the regulation of metabolism and global transcription through metabolomic and transcriptomic analyses. The results demonstrated that the depletion of PSMA inhibits the proliferation and migration of LNCaP androgen-dependent PCA cells and 22Rv1 CRPC cells.

Materials and methods

Clinical samples

Normal prostate tissues (n = 14) and PCA tissues (n = 14) were obtained from the Biological Tissue Sample Bank of the Department of Urology, Nanjing First Hospital. All samples were cryopreserved in liquid nitrogen and pathologically identified. The use of tissues was in accordance with ethical codes and approved by the Institutional Review Committee of Nanjing First Hospital.

Cell culture

The human androgen-dependent PCA cell line LNCaP and the CRPC cell line 22rv1 were purchased from the Cell Bank of Shanghai Chinese Academy of Sciences (Shanghai China). The LNCaP and 22rv1 cells were cultured in RPMI 1640 medium (Gibco; CA, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin and streptomycin. All the cells were cultured with 5% CO2 and 95% humidity at 37°C.

Lentivirus infection

The PSMA gene was used as a template for the design of RNA interference target sequences by GeneChem (Shanghai, China). The sequences are listed in Table S1. The shRNA was packaged into GV493 lentiviral vectors with puromycin resistance, and the resulting vectors were used for infection according to the manufacturer’s instructions once the cells reached 70–80% confluence (MOI\textsuperscript{LNCaP} = 10, MOI [13,1] = 5). The cells were subsequently cultured with 5% CO2 and 95% humidity at 37°C for 48 h and then in medium containing puromycin (2.00 μg/ml) for 72 h to identify the stable knockdown cells[14].

Metabolomic and transcriptome analyses

LNCaP cells were transduced with 10 pairs of shNC or shPSMA for untargeted metabolomics, and another 3 pairs were used for transcriptome analysis. HPLC-MS/MS was conducted by GeneChem (Shanghai, China). The samples were analyzed by HPLC-MS/MS using a TripleTOF™ 6600 plus mass spectrometer (AB SCIEX, USA) coupled to an Agilent 1290 liquid chromatography system (Agilent, USA). ProteoWizard (version 3.0.6150) was used to convert the raw MS data files to mzXML format and the MS2 data files to mgf format. All MS files (mzXML format) were processed using the R package ‘XCMS’ (version 1.46.0) for peak detection and alignment. Metabolite identification was achieved with MetDNA (http://metdna.zhulab.cn/) using the MS1 peak table and MS2 data files (mgf format). The MS1 peak table was uploaded to MetaboAnalyst (https://www.metaboanalyst.ca) for the identification of differential metabolites. Principal component analysis (PCA) and partial least squares discrimination analysis (PLS-DA) were performed using a peak table normalized by the total intensity to investigate the potential separation of metabolite profiles between the control and MG samples, and fold changes and p-values (assessed by Student’s t-test) were computed. The discovery dataset contained 32,437 features, and differential features with fold changes greater than 1.5, a P value less than 0.05, and a VIP value higher than 1 were selected[15]. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database (http://www.genome.jp/kegg/) was used to analyze the pathways of the differential metabolites[15].

Total mRNA was isolated for transcriptome analysis, and the purity and integrity of the mRNA samples were assessed using a NanoPhotometer®
spectrophotometer (IMPLEN, CA, USA) and an RNA Nano 6000 Assay Kit with the Bioanalyzer 2100 system (Agilent Technologies, CA, USA). Sequencing libraries were generated using the NEBNext Ultra™ RNA Library Prep Kit for Illumina® (NEB, USA) following the manufacturer’s recommendations. The library quality was assessed using the Agilent Bioanalyzer 2100 system. FeatureCounts v1.5.0-p3 was used to count the read numbers mapped to each gene, and the FPKM value of each gene was then calculated based on the length of the gene and the read count mapped to the gene. Prior to differential gene expression analysis, the read counts were adjusted using the edgeR program package based on one scaling normalized factor. The differential expression analysis of two groups was performed using the edgeR R package (3.18.1). The P values were adjusted using the Benjamini & Hochberg method. A corrected P-value of 0.05 and an absolute fold change of 2 were set as the thresholds for significantly differential expression. The cluster Profiler R package was used to perform gene ontology (GO) and KEGG enrichment analyses. The GO terms and KEGG pathways with corrected P values less than 0.05 were considered significantly enriched[16].

Detection of arginine and proline levels

The concentrations of arginine and proline were detected using arginine assay kits (ab24108) and proline assay kits (ab282913) (Abcam, Cambridge, UK) [17]. The experiments were performed according to the manufacturer’s instructions.

Real-time quantitative polymerase chain reaction (RT-qPCR)

RNA-easy Isolation Reagent (Vazyme, Suzhou, China) was used for the isolation of total RNA according to the manufacturer’s instructions. The RNA was reverse transcribed by reverse transcriptase (Vazyme, Suzhou, China), and the relative mRNA levels were determined by RT-qPCR using a QuantStudio™ 3 system (ABI, MA, USA). All real-time qPCR assays were performed using SYBR Green Master Mix (Vazyme, Suzhou, China). The program used for RNA amplification included an initial denaturing step of 95°C for 5 min and 40 cycles of 10 s at 95°C and 30 s at 60°C. The comparative ΔΔCq method was used to determine the relative amount of mRNA [18]. The primer sequences are listed in Table S2.

Western blotting

Proteins were extracted using a total protein extraction kit (KeyGEN BioTECH, Shanghai, China) according to the manufacturer’s instructions. The proteins were resolved by gel electrophoresis using 8%-15% sodium dodecyl sulfate (SDS)-polyacrylamide gels and then transferred to a nitrocellulose membrane. The membrane was blocked with 5% skim milk and then incubated with primary antibodies diluted with 3% BSA at room temperature for 1.5 h and then with secondary antibodies for 1 h. The target bands were detected by ECL substrate (Vazyme, Suzhou, China). The antibodies and dilution ratios are listed in Table S3. [19]

CCK-8 assay

LNCaP and 22rv1 cells were cultured in 96-well plates at a density of 2000 cells/well, and the proliferation of the cells was detected 0, 1, 2, 3, 4 and 5 days after the knockdown of PSMA. Ten microliters of CCK-8 solution (Dojindo, Kumamoto, Japan) was added to each well, and the cells were incubated at 37°C for 1 h. The absorbance of each well at 450 nm was measured with a microplate reader (TWIN200PRO, TECAN, Swiss) [20].

Colony formation assay

Virus-transfected cells at the logarithmic phase of growth were digested with 0.25% trypsin and agitated in 10% FBS culture medium to obtain a single-cell suspension. Two hundred fifty cells were inoculated in each well of a 6-well plate. The plates were cultured at 37°C with 5% CO2 and saturated humidity. When colonies visible to the naked eye appeared in the 6-well plate, the culture was terminated, the supernatant was discarded, and the cells were washed twice with PBS and then fixed in 4% paraformaldehyde for 15 min. After two washes with 1× PBS, the cells were
dyed with 1% crystal violet for 15 min. Clone clusters with more than 10 cells were counted under a microscope (NIKON TI, Tokyo, Japan)[21].

Transwell assay

Transwell inserts (Corning, Corning, USA) were placed into 24-well plates. Matrigel (Corning, Corning, USA) and medium were mixed at a ratio of 1:6 and added to each upper chamber (60 µl per well). After the chambers were incubated at 37°C for 1 h, cells suspended in serum-free medium at a density of 250 cells/µl were added to each upper chamber (200 µl of the suspension, 5 × 10⁴ cells per well). The lower chamber was filled with 600 µl of complete culture medium with 10% FBS. The cells were cultured with 5% CO2 and 95% humidity at 37°C for 72 h, and the chamber was then washed three times with 1× PBS, fixed with methanol for 15 min and stained with 0.2% crystal violet for 15 min at room temperature. The numbers of invading cells in three random fields under a microscope (NIKON TI, Tokyo, Japan) at 400× magnification were counted. The experiments were repeated three times[20].

Wound healing assay

After the knockdown of PSMA, the cells were seeded into 6-well plates and cultured to 100% confluence. A scratch was made with the tip of a 10-µl micropipette. The cells were cultured in serum-free medium, and the wound was photographed at 0 and 48 h after the scratch was made with a microscope (NIKON TI, Tokyo, Japan). The experiments were repeated three times[22].

Tumor xenograft experiments

Twelve nude mice (male, 4 weeks) were randomly divided into two groups of six mice each. Wild-type 22rv1 cells and PSMA-depleted 22rv1 cells were suspended in normal saline at a density of 1 × 10⁷/ml. Matrigel (Corning, Corning, USA) was added to the suspension at a ratio of 1:1, and 200 µl of the mixture was subcutaneously injected into the axilla to induce tumor growth. Every week, the tumors were measured using a Vernier caliper. The tumor volumes were calculated as follows: \( V_t = 0.5 \times L \times W \) [2], where L is the length and W is the width. After 28 days, the mice were sacrificed, and the sizes and weights of the tumors were measured. All animal research was approved and performed in strict accordance with the institutional ethical guidelines of the Committee on the Use of Live Animals of Nanjing First Hospital, Nanjing Medical University. [14]

Statistical analysis

All experiments performed in this study were independently repeated a minimum of three times. The data are expressed as the means ± SDs and were analyzed using SPSS 19.0 (Statistical Product and Service Solutions, USA). The differences between means were analyzed by a two-tailed Student’s t test, and differences among three or more means were analyzed by analysis of variance (ANOVA). A P-value < 0.05 was indicative of a significant difference.

Results

In the present study, we aimed to investigate the role of PSMA in the progression of PCa through metabolomic and transcriptomic analyses. The experimental results demonstrated that the depletion of PSMA could promote the biosynthesis of arginine and lysine. Elevated arginine levels inhibited the proliferation and migration of PCa cells by inhibiting the expression of AR and promoting the expression of c-Fos and FosB. Therefore, our data confirm the function and mechanism of PSMA in PCa and provide new insights for the development of treatments for PCa.

PSMA was highly expressed in PCa

We used GEPIA2 to analyze the data from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx). The results from the pan-cancer analysis demonstrated that PSMA expression was significantly higher in PCa than in other organs and tumors (Figure 1(a, b)). GEPIA2 was then used to analyze the expression of PSMA in PCa based on the GTEx and TCGA
datasets. The results suggested that PSMA was overexpressed in PCa (Figure 1(c)). The results of the UALCAN analysis of the dataset from TCGA demonstrated that the high expression level of PSMA was correlated with more nodal metastasis (Figure 1(d)). Our RT-qPCR results (Figure 1(e)) demonstrated that PSMA was overexpressed in PCa tissues, and this finding was verified by Western blotting (Figure 1(f)) and grayscale analysis (Figure 1(g)).

**PSMA was involved in PCa metabolic pathways**

To further investigate the function of PSMA, PSMA-knockdown LNCaP and 22rv1 cells were constructed (Figure 2(a-c)). Because PSMA has glutamic carboxypeptidase and folate hydrolase activities, we performed a metabonomic analysis of PSMA-knockdown LNCaP cells to analyze the role of PSMA in tumor metabolism. The heatmap revealed significant differences in metabolites between the control and PSMA-knockdown group (Figure 2(d)).

![Figure 1](image.png)

**Figure 1.** PSMA is overexpressed in PCa tissues. A and B. The online analysis platform GEPIA2 (http://gepia2.cancer-pku.cn/#index) was used to analyze the expression of PSMA across multiple cancers based on data from the GTex (https://commonfund.nih.gov/GTex) and TCGA (https://cancergenome.nih.gov/abouttcga/overview) databases. A is dot plot and B is bar plot. C. GEPIA2 was used to compare the expression of PSMA between PCa and normal prostate tissues. D The online analysis platform UALCAN was used to analyze the relationship between PSMA expression and nodal metastasis. E. The expression of PSMA in PCa tissues was analyzed by RT-qPCR. F. The expression of PSMA in PCa tissues was detected by Western blotting. G. The Western blotting results were measured by grayscale analysis. (*P < 0.05, **P < 0.01, ***P < 0.001).
metabonomic analysis detected 2353 high-expression peaks and 92 low-expression peaks (Figure 2(e)). In addition, a correlation analysis found strong correlations between different metabolites (Figure 2(f)). To further clarify the biological functions of the altered metabolites, a pathway annotation...
analysis was performed, and the results demonstrated that the depletion of PSMA affected pyruvate metabolism, purine metabolism, arginine and proline metabolism and other metabolic pathways (Figure 2(g)). The top ten pathways with the differentially enriched metabolites are listed in Table S4.

**PSMA knockdown resulted in transcription abnormalities in PCA**

To investigate whether the metabolic changes induced by PSMA knockdown are related to abnormal cell transcription, we conducted a transcriptome analysis and found that 172 and 418 genes were upregulated and downregulated, respectively, after PSMA knockdown (Figure 3(a)). We sorted the differentially expressed genes based on their fold change and identified the top 50 upregulated genes and the top 50 downregulated genes (Figure 3(b)). The GO enrichment analysis revealed that the altered genes were enriched in response to type I interferon, extracellular matrix disassembly and some other biological processes. Most proteins encoded by the altered genes were localized in the extracellular matrix and basement membrane. The analysis of molecular function showed that the proteins encoded by the altered genes were primarily involved in the regulation of G protein-coupled receptors, chemokine activity and cytokine activity (Figure S1). A KEGG enrichment analysis showed that PSMA knockdown altered cytokine-cytokine receptor interactions, the IL-17 signaling pathway, the TNF signaling pathway and many other signaling pathways (Figure 3(c)). The top ten pathways identified by the KEGG enrichment analysis are listed in Table S5. A disease ontology (DO) enrichment analysis revealed that the altered genes were mainly involved in the occurrence and development of cancer (Figure 3(d)). The top ten pathways identified by the DO enrichment analysis are listed in Table S6. The results of the DisGeNET enrichment analysis showed that the altered genes were enriched in hepatitis B, gastritis, epithelioma, acute pancreatitis and some other diseases (Figure 3(e)), and the top ten diseases identified by the DisGeNET enrichment analysis are listed in Table S6. The Reactome enrichment analysis demonstrated that PSMA knockdown induced alterations in chemokine binding to chemokine receptors, interferon signaling, extracellular matrix organization and GPCR ligand binding (Figure 3(f)). The top ten pathways of the differentially expressed genes identified based on the Reactome enrichment analysis are listed in Table S7.

**The abnormal transcription induced by PSMA knockdown was related to arginine and proline metabolism**

To find the link between the metabolic and transcriptional changes caused by PSMA depletion, we performed a joint analysis of the two omics results. First, a correlation analysis showed that the differentially expressed genes were correlated to the differentially produced metabolites (Figure 4(a)). We then combined the metabolomic and transcriptome results, performed a KEGG pathway analysis using the resulting dataset and generated bubble maps of the top 50 pathways (Figure 4(b)). To determine the relationship between the differentially expressed genes and differentially expressed metabolites, we selected the 15 metabolome pathways and 15 transcriptome pathways with the highest fold change. Only the metabolites and key genes related to the arginine and proline metabolism pathways showed simultaneous changes (Figure 4(c)). To facilitate visualization of these commonalities, a pathway network analysis of arginine and proline metabolism, the TNF signaling pathway, pyrimidine metabolism, purine metabolism and phenylalanine metabolism was performed using Cytoscape (Figure S2).

**PSMA knockdown inhibited PCA metastasis via epithelial-mesenchymal transformation (EMT)**

The results from the omics studies suggested the involvement of PSMA in extracellular matrix disassembly and organization. We examined the effect of PSMA knockdown on the migration and invasion of PCA cells through scratch and Transwell assays, respectively. The scratch assay demonstrated that PSMA knockdown inhibited the migration of LNCaP (P = 0.0003) and 22rv1 cells (P = 0.0003) (Figure 5(a)), and the Transwell assays demonstrated that PSMA knockdown inhibited the invasion of LNCaP (P = 0.0001) and 22rv1 (P = 0.0006) cells (Figure 5(b)). To further explore the mechanism through which PSMA knockdown inhibited the migration and
invasion of PCa cells, we detected the expression of key EMT proteins. The knockdown of PSMA downregulated the expression of matrix metalloproteinase 7 (MMP7), matrix metalloproteinase 9 (MMP9) and N-cadherin and upregulated that of E-cadherin (Figure 5(c, d)).
PSMA knockdown inhibited the proliferation of PCa cells

Because PSMA knockdown led to metabolic disorders and abnormal transcription, we hypothesized that the loss of PSMA might affect the proliferation of PCa cells. The results from CCK-8 assays demonstrated that PSMA knockdown inhibited the proliferation of LNCaP (P = 0.0012) and 22rv1 (P < 0.0001) cells (Figure 6(a)). EdU assays also suggested that PSMA knockdown inhibited the proliferation of LNCaP (P = 0.0042) and 22rv1 (P = 0.0448) cells (Figure 6(b)). Moreover, PSMA knockdown significantly inhibited the colony formation of LNCaP (P = 0.0375) and 22rv1 (P = 0.0002) cells (Figure 6(c)). Tumor xenograft experiments were performed to detect the influence of PSMA depletion on the growth of PCa cells in vivo. We injected wild-type and PSMA-depleted 22Rv1 cells into nude mice and
measured the tumor volume and growth after 28 days. The tumor growth and volume found in nude mice injected with wild-type 22Rv1 cells were significantly higher than the corresponding values ($P = 0.0003$ and $P = 0.0011$) found in nude mice injected with PSMA-depleted 22Rv1 cells (Figure 6(d-f)).

**PSMA knockdown modulated the expression of AR and c-Fos by regulating the biosynthesis of arginine**

The results suggested that the arginine and proline pathways were transformed at both the metabolic and transcriptional levels after PSMA knockdown. Therefore, the changes in arginine metabolism observed in LNCaP ($P < 0.0001$) and 22RV1
cells after PSMA knockdown were measured using kits purchased from Abcam. The results showed that PSMA knockdown promoted the biosynthesis of arginine and proline. We also detected the concentration of proline in LNCaP (P = 0.0022) and 22rv1 (P = 0.0014) cells (Figure 7(a)). Previous studies have reported that PSMA is significantly upregulated after antiandrogen therapy, but whether PSMA affects AR signaling is unclear. The transcriptomic analysis revealed that PSMA knockdown altered the expression of genes associated with the AR and
Figure 7. PSMA knockdown promoted the biosynthesis of arginine and proline, inhibited the AR signaling pathway and activated the FOS signaling pathway. A. An L-arginine assay kit and L-proline assay kit purchased from Abcam were used to measure the concentrations of arginine and proline. B. Gene count of differentially expressed genes related to the AR signaling pathway and FOS signaling pathway in the transcriptome. C. The expression of AR and PSA was detected by RT-qPCR. D. The expression of AR and PSA was detected by Western blotting. E. The expression of c-Fos, FosB, p-c-Fos, c-Jun, p-c-Jun, JunB and Jund was detected by Western blotting. F. The expression of c-FOS and c-Jun was detected by Western blotting. G. The efficiency of ASS1 knockdown was assessed by RT-qPCR. H. The efficiency of ASS1 knockdown was assessed by Western blotting. I. After the knockdown of both PSMA and ASS1, kits were used to detect the concentrations of arginine and proline. J. The expression of AR, PSA, c-Fos and FosB after the knockdown of both PSMA and ASS1 was measured by RT-qPCR. K. The expression of AR and PSA after the knockdown of both PSMA and ASS1 was detected by Western blotting. L. The change in the expression of c-Fos and FosB after the knockdown of both PSMA and ASS1 was measured by Western blotting. (*P < 0.05, **P < 0.01, ***P < 0.001).
FOS signaling pathways (Figure 7(b)). A DisGeNET enrichment analysis indicated that some of the differentially expressed genes were related to androgen-independent PCa (Figure 3(e)). Therefore, we performed Western blotting and RT-qPCR assays to detect the expression of AR and its downstream target genes. The results showed that AR signaling was significantly inhibited in LNCaP and 22rv1 cells (Figure 7(c, d)). In addition, the results from the data analysis revealed that the expression of c-Fos and FosB, which are important components of AP-1, was significantly increased after PSMA knockdown. The Western blotting and RT-qPCR results demonstrated that PSMA knockdown in LNCaP and 22rv1 cells upregulated the expression of FosB and c-Fos but did not alter the Junb, Jund and c-Jun expression levels (Figure 7(e, f)). The activation of c-Fos and c-Jun is regulated by phosphorylation. Therefore, we detected the phosphorylation level of c-Fos at serine 362 and c-Jun at serine 63 and 73 (Figure 7(e, f)) and found that the phosphorylation of c-Fos at serine 362 was significantly increased after the knockdown of PSMA.

Conversion from other amino acids constitutes the main source of arginine. Argininosuccinate synthase 1 (ASS1) catalyzes the penultimate step of arginine biosynthesis and is a recognized rate-limiting enzyme for arginine synthesis [13]. The efficiency of ASS1 knockdown was detected by RT-qPCR (Figure 7(g)) and Western blotting (Figure 7(h)). To investigate whether arginine metabolism induces transcription abnormalities, we inhibited arginine biosynthesis by knocking down ASS1 (Figure 7(i)). The RT-qPCR results demonstrated that the knockdown of ASS1 restored the abnormal transcription of AR, PSA, c-Fos and FosB induced by PSMA knockdown (Figure 7(j)). The Western blotting results also supported this finding (Figure 7(k, l)). We also examined the effect of ASS1 knockdown on cell function, and CCK-8 (Figure 8(a)), wound healing (Figure 8(b)) and Transwell assays (Figure 8(c)) demonstrated that ASS1 knockdown restored the changes in cell functions induced by PSMA knockdown.

Discussion

The striking upregulation of PSMA during oncogenesis and PCa progression has been recognized for many years [23]. Although several studies have shown that PSMA is widely expressed in PCa and metastases, its biological function and mechanism of action have remained unclear [24, 25]. The role of PSMA in PCa metastasis is controversial. One study demonstrated that inhibiting the enzymatic activity of PSMA promotes tumor metastasis [25], whereas other studies have suggested that PSMA overexpression increases the invasive ability of PCa cell lines [26]. The data from the GTEx and TCGA databases showed that PSMA expression was markedly higher in PCa than in other tumors, and the high expression of PSMA was associated with distant lymph node metastasis.

We found that PSMA expression was elevated in the majority of PCa cases. However, we found no significant difference in PSMA expression in some groups, such as numbers 7 and 9 in Figure 1(f). As reported, PSMA is not expressed in the PCa cell line PC-3 [27], which indicates that the expression of PSMA may be related to the pathology of PCa. It has been reported that PSMA-targeted imaging could be disabled to delineate neuroendocrine PCa (NEPC) lesions due to suppression of the PSMA gene (FOLH1) [28]. In addition, the loss of PSMA expression in patients with acinar PCa after chemotherapy has also been reported [29]. In addition to the above reasons, the inconsistent expression of PSMA in PCa may also be related to the method used for tissue acquisition. In general, the location of PCa foci exhibits notable pathology, and the tissue is collected from the foci. Unlike kidney cancer, PCa is multifocal and does not include a capsule [30]. Therefore, when collecting PCa tissue, it is difficult to accurately distinguish PCa tissue from surrounding tissue. A lower Gleason score reflects fewer and smaller lesions [31]. In patients with low Gleason scores, the tumor tissue obtained may be mixed with some surrounding tissue.

The results of the present study demonstrated that PSMA knockdown inhibited the invasion of LNCaP and 22rv1 cells. Paulus Tsui et al. reported that PSMA can also be used as a marker of tumor
angiogenesis in PCa [32]. Another study suggested that PSMA can be used as a sensitive marker of bone metastasis [33]. PSMA-based radionuclide $^{68}$Ga PET-CT has become an effective method for detecting bone metastasis in PCa [34,35]. The omics analyses showed that PSMA knockdown decreased the expression of MMP7 and affected extracellular matrix disassembly and organization. The proteases secreted by the MMP family can breakdown proteoglycans, fibronectin, elastin and casein and promote tumor metastasis. As a member of the MMP family, MMP-7 promotes PCa-induced osteolysis via solubilization of the TNF family member receptor activator of nuclear κB ligand (RANKL) [36]. Recent studies have shown that the serum MMP7 levels could guide therapy for metastatic PCa [37]. These results suggest that PSMA knockdown may

Figure 8. ASS1 knockdown restored the functional change induced by PSMA knockdown. A. CCK-8 assays were performed to detect the effect of ASS1 knockdown on the proliferation of PCa cells. B. Wound healing assays were performed to assess the influence of ASS1 knockdown on the migration of PCa cells. C. The effect of ASS1 knockdown on the invasion of PCa cells was assessed by Transwell assays. ($^*$P < 0.05, **P < 0.01, ***P < 0.001).
inhibit PCa metastasis by decreasing MMP7 expression. However, the mechanism through which PSMA affects MMP7 transcription needs further study.

In the present study, we also found that PSMA knockdown promoted the biosynthesis of arginine and proline. A previous study reported that a nutritional formulation consisting of lysine, proline, arginine, ascorbic acid and epigallocatechin gallate can inhibit PCa invasion by altering MMP expression [38], which indicates that PSMA may regulate the expression of MMP7 and MMP9 by altering the biosynthesis of arginine and proline. Another study found that the tyrosine-isoleucine-glycine-serine-N-arginine (YIGSR) peptide of laminin, which corresponds to the 929–933 sequence of the beta1 chain, can inhibit PCa cell proliferation and invasion by competitively binding to the polyphenol (-)epigallocatechin-3-gallate (ECCG)-binding sites. In addition, YIGSR decreased the mitochondrial membrane potential, inhibited ATP biosynthesis and increased caspase-9 activity [39]. In addition, the function of arginine may be related to its ability to be methylated. Currently, multiple lines of evidence suggest that protein arginine methyltransferase 5 (PRMT5) and serine arginine protein kinase 1 (SAPK1) are potential therapeutic targets for PCa [40–42].

As important components of the transcription factor AP-1, c-Fos and FosB were significantly upregulated after PSMA knockdown. c-Fos has been considered an oncogene for a long time [43,44], but recent studies have demonstrated that c-Fos may act as a tumor suppressor in PCa [45]. Data mining showed that c-Fos was decreased in PCa and further downregulated in distant metastatic lesions. The results from cell function experiments showed that c-Fos knockdown induced cell proliferation and changes in oncogenic pathways. In PTEN-mutated PCa, c-Fos depletion can induce proliferation and metastasis [45]. Another study demonstrated that the activation of GPR30 inhibits the growth of PCa cells via activation of the c-Jun/c-Fos-dependent upregulation of p21 [46]. Our results indicated that arginine biosynthesis induced c-Fos transcription.

In addition, we found that PSMA knockdown activated AR signaling. Due to the high accuracy of $^{68}$Ga-PSMA-PET-CT in diagnosing the biochemical recurrence and distant metastasis of PCa, researchers have tended to focus on the changes in PSMA expression in response to different types of ADT [47–49], but whether PSMA affects AR signaling has not been confirmed. X Deng et al. demonstrated that PRMT5 was enriched in the AR promoter region by interacting with SP1 and methylated histone H4R3 and formed a complex with the ATP-dependent chromatin remodeling protein Brg1 [42]. In addition, PRMT5 can promote pICln-dependent AR transcription in CRPC [50], which suggests that the metabolism of arginine regulates the expression of AR through histone H4R3 methylation. We demonstrated that biosynthesis inhibited AR signaling, but the specific mechanism through which arginine regulates AR signaling needs further study.

As a nonessential amino acid, proline plays an important role in the development of various tumors [51,52]. The metabolism of proline is regulated by the c-MYC and PI3K pathways, both of which are critical in tumorigenesis and progression [53,54]. Additionally, the phosphorylation of the proline-rich domain of WAVE3 drives its oncogenic activity in breast cancer [55]. However, the role and mechanism of proline in PCa have rarely been studied in recent years. The p53 Arg72Pro SNP is associated with an increased risk of various malignancies but is the only SNP associated with an increased risk of PCa [56]. In addition, proline mediates the serine phosphorylation of AR induced by cyclin D3/CDK11p58 and can regulate the transcriptional activity of AR [57]. However, whether proline biosynthesis is involved in the regulation of the AR and FOS signaling pathways has not yet been studied.

**Conclusion**

In summary, PSMA knockdown can inhibit PCa cell proliferation and metastasis as well as decrease AR expression and promote c-Fos and FosB expression by increasing arginine biosynthesis. The function and mechanism of PSMA in amino acid metabolism in PCa deserve the attention of researchers. The PSMA-mediated modulation of transcription through the regulation of arginine
and proline metabolism has the potential to be a therapeutic target for PCa.

Acknowledgements

We appreciate the open access databases of TCGA and GTEx. We would like to thank the individuals who maintain the online analysis platforms GEPIA2 (GEPIA 2.cancer-pku.cn/#index) and UALCAN (http://ualcan.path.uab.edu). Furthermore, we would like to thank American Journal Experts (www.aje.com) for providing English language editing services.

Funding

This work was supported by The National Natural Science Foundation of China (Grants 92049111 and 81570613) and Jiangsu Provincial Department of Science and Technology (BE2017615).

Highlights

- PSMA depletion inhibited the proliferation, migration and invasion of prostate cancer cells.
- PSMA depletion promoted the biosynthesis of arginine and proline.
- PSMA depletion inhibited the function of the AR signaling pathway.
- PSMA depletion promoted the expression of c-Fos and FosB, which are components of the transcription factor AP1.

Disclosure statement

No potential conflict of interest was reported by the author(s).

ORCID

Xi Hong @ http://orcid.org/0000-0002-9565-1919

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
[2] Santos AF, Huang H, Tindall DJ. The androgen receptor: a potential target for therapy of prostate cancer. Steroids. 2004;69(2):79–85.
[3] sDel Re M, Conteduca V, Crucitta S, et al. Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with Abiraterone and enzalutamide. Prostate Cancer Prostatic Dis. 2021;24(2):524–531.
[4] Tian S, Lei Z, Gong Z, et al. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review. Cancer Cell Int. 2020;20(1):409.
[5] Carlsson SV, Tafe LJ, Chade DC, et al. Pathological features of lymph node metastasis for predicting biochemical recurrence after radical prostatectomy for prostate cancer. J Urol. 2013;189(4):1314–1318.
[6] Sun Y, Chen G, He J, et al. Clinical significance and potential molecular mechanism of miRNA-222-3p in metastatic prostate cancer. Bioengineered. 2021;12(1):325–340.
[7] Liu J, Li J, Ma Y, et al. MicroRNA miR-145-5p inhibits Phospholipase D 5 (PLDS) to downregulate cell proliferation and metastasis to mitigate prostate cancer. Bioengineered. 2021;12(1):324–3251.
[8] Fu D, Zang L, Li Z, et al. Long non-coding RNA CRNDE regulates the growth and migration of prostate cancer cells by targeting microRNA-146a-5p. Bioengineered. 2021;12(1):2469–2479.
[9] Rahbar K, Afshar-Oromieh A, Jadvar H, et al. PSMA Theranostics: current Status and Future Directions. Mol Imaging. 2018;17:1536012118776068.
[10] Afshar-Oromieh A, Babich JW, Kratochwil C, et al. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. J Nucl Med. 2016;57(Supplement 3):79s–89s.
[11] Caromile LA, Dortche K, Rahman MM, et al. PSMA redirects cell survival signaling from the MAPK to the PI3K-akt pathways to promote the progression of prostate cancer. Sci Signal. 2017;10(470). DOI:10.1126/scisignal.aag3326.
[12] Grauer LS, Lawler KD, Marignac JL, et al. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res. 1998;58(21):4787–4789.
[13] Qiu F, Chen Y-R, Liu X, et al. Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal. 2014;7(319):ra31.
[14] Ding M, Jiang C-Y, Zhang Y, et al. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer. J Exp Clin Cancer Res. 2020;39(1):28.
[15] Shen X, Wang R, Xiong X, et al. Metabolic reaction network-based recursive metabolite annotation for untargeted metabolomics. Nat Commun. 2019;10(1):1516.
[16] Hrdlickova R, Toloue M, Tian B. RNA-Seq methods for transcriptome analysis. Wiley Interdiscip Rev RNA. 2017;8(1). DOI:10.1002/wrna.1364.
[17] Zhao Z, Zhang P, Li W, et al. Pegylated Recombinant Human Arginase 1 Induces Autophagy and Apoptosis via the ROS-activated AKT/mTOR Pathway in Bladder Cancer Cells. Oxid Med Cell Longev. 2021;2021:5510663.
[18] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402–408.

[19] Yang PC, Yang PC. Western blot: technique, theory, and trouble shooting. N Am J Med Sci. 2012;4(9):429–434.

[20] Han Y, Wen X, Li X, et al. Circular RNA hsa_circ_0075542 acts as a sponge for microRNA-1197 to suppress malignant characteristics and promote apoptosis in prostate cancer cells. Bioengineered. 2021;12(1):5620–5631.

[21] Zhang SF, Zhang K, Cheng HM, et al. Comparative transcriptomics reveals colony formation mechanism of a harmful algal bloom species Phaeocystis globosa. Sci Total Environ. 2020;719:137454.

[22] Martinotti S, Ranzato E. Scratch Wound Healing Assay. Methods Mol Biol. 2020;2109:225–229.

[23] Wynant GE, Murphy GP, Horoszewicz JS, et al. Immunosciingraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT-356). Prostate. 1991;18(3):229–241.

[24] Wolf P, Freudenberg N, Bühler P, et al. Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. Prostate. 2010;70(5):562–569.

[25] Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256–2261.

[26] Yao V, Bacich DJ. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate. 2006;66(8):867–875.

[27] Lee SJ, Zhang Y, Lee SD, et al. Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. Mol Ther. 2004;10(6):1051–1058.

[28] Bakht MK, Derecichei I, Li Y, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2018;26(2):131–146.

[29] Bronsert P, Reichel K, Ruf J. Loss of PSA Expression in Non-neuroendocrine Dedifferentiated Acinar Prostate Cancer. Clin Nucl Med. 2018;43(7):526–528.

[30] Tourinho-Barbosa RR, de La Rosette J, Sanchez-Salas R. Prostate cancer multifocality, the index lesion, and the microenvironment. Curr Opin Urol. 2018;28(6):499–505.

[31] Margolis DJ. Multimparametric MRI for localized prostate cancer: lesion detection and staging. Biomed Res Int. 2014;2014:684127.

[32] Tsui P, Rubenstein M, Guinan P. Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesis. J Biomed Biotechnol. 2005;2005(3):287–290.

[33] Huang H, Guma SR, Melamed J, et al. NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens. Am J Clin Exp Urol. 2018;6(5):182–188.

[34] Hammes J, Täger P, Drzezga A. EBONI: a Tool for Automated Quantification of Bone Metastasis Load in PSMA PET/CT. J Nucl Med. 2018;59(7):1070–1075.

[35] Pomykala KL, Czernin J, Grogan TR, et al. Total-Body 68 Ga-PSMA-11 PET/CT for Bone Metastasis Detection in Prostate Cancer Patients: potential Impact on Bone Scan Guidelines. J Nucl Med. 2020;61(3):405–411.

[36] Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell. 2005;7(5):485–496.

[37] Tregunna R. Serum MMP7 levels could guide metastatic therapy for prostate cancer. Nat Rev Urol. 2020;17:658.

[38] Roomi MW, Ivanov V, Kalinovsky T, et al. Anti-tumor effect of ascorbic acid, lysine, proline, arginine, and epigallocatechin gallate on prostate cancer cell lines PC-3, LNCaP, and DU145. Res Commun Mol Pathol PharmacolResearch. 2004;115-116:251–264.

[39] Yu HN, Zhang LC, Yang JG, et al. Effect of laminin tyrosine-isoleucine-glycine-serine-arginine peptide on the growth of human prostate cancer (PC-3) cells in vitro. Eur J Pharmacol. 2009;616(1–3):251–255.

[40] Mayrovou A, Brakspear K, Hamdollah-Zadeh M, et al. Serum-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene. 2015;34(33):4311–4319.

[41] Bullock N, Potts J, Simpkin AJ, et al. Serum-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion. J Clin Pathol. 2016;69(2):171–175.

[42] Deng X, Shao G, Zhang H-T, et al. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth. Oncogene. 2017;36(9):1223–1231.

[43] Verma IM, Sassone-Corsi P. Proto-oncogene fos: complex but versatile regulation. Cell. 1987;51(4):513–514.

[44] Cui Y, Wang Y, Deng J, et al. Chrysolite effects on the expression of anti-oncogenic P53 and P16 and oncogene C-jun and C-fos in Wistar rats’ lung tissues. Environ Sci Pollut Res Int. 2018;25(23):22378–22388.

[45] Riedel M, Berthelsen MF, Cai H, et al. In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun. Oncogene. 2021;40(13):2437–2447.

[46] Chan CK, Lam H-M, Ng C-F, et al. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death Differ. 2010;17(9):1511–1523.

[47] Bakht MK, Oh SW, Youn H, et al. Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted
Agents: emerging Opportunities and Challenges. Nucl Med Mol Imaging. 2017;51(3):202–211.

[48] Batra JS, Pienta KJ, Pomper MG, et al. Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications? Transl Androl Urol. 2019;8(S3):S263–s264.

[49] Vaz S, Hadaschik B, Gabriel M, et al. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020;47(1):9–15.

[50] Beketova E, Fang S, Owens JL, et al. Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer. Cancer Res. 2020;80(22):4904–4917.

[51] Phang JM. Proline Metabolism in Cell Regulation and Cancer Biology: recent Advances and Hypotheses. Antioxid Redox Signal. 2019;30(4):635–649.

[52] Phang JM. Proline metabolism and cancer. Front Biosci (Landmark Ed). 2012;17(1):1835–1845.

[53] Liu W, Le A, Hancock C, et al. Reprogramming of proline and glutamine metabolism contributes to the proliferative and metabolic responses regulated by oncogenic transcription factor c-MYC. Proc Natl Acad Sci U S A. 2012;109(23):8983–8988.

[54] Wang H, Zhang Q, Wen Q, et al. Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal. 2012;24(1):17–24.

[55] Kansakar U, Wang W, Markovic V, et al. Phosphorylation of the proline-rich domain of WAVE3 drives its oncogenic activity in breast cancer. Sci Rep. 2021;11(1):3868.

[56] de Sousa IH, Campos VNS, Vale AAM, et al. Ruthenium (II) complexes with N, O-chelating proline and threonine ligands cause selective cytotoxicity by the induction of genomic instability, cell cycle arrest and apoptosis in breast and prostate tumor cells. Toxicol In Vitro. 2020;62:104679.

[57] Funderburk SF, Shatkina L, Mink S, et al. Specific N-terminal mutations in the human androgen receptor induce cytotoxicity. Neurobiol Aging. 2009;30(11):1851–1864.